Author - Michelle Carr

Titan Pharmaceuticals

Kate DeVarney joins Titan Pharma’s Board

Kate DeVarney, EVP and CSO of Titan Pharmaceuticals (NASDAQ:TTNP), was elected to the board at the company’s annual meeting. Dr. DeVarney, a clinical neuropsychologist by training, joined Titan in January...

Analysts downgrade and lower PTs for Aduro Biotech

William Blair downgraded Aduro Biotech (NASDAQ:ADRO) to “market perform” from “outperform” and H.C. Wainwright cut its price target for Aduro after Novartis removed Aduro’s intratumoral STING agonist, ADU-S100, from its...


Soricimed updates peptide-drug conjugate program

Closely-held Soricimed Biopharma updated its peptide-drug conjugate (PDC) program, which enables delivery of a cytotoxic drug payload bound to a targeting peptide directly to receptors that are overexpressed by cancer...


SVB Leerink starts 89bio at OP; PT $55

SVC Leerink initiated coverage of 89bio (NASDAQ:ETNB) with an “outperform” rating and $55 price target. The stock closed at $28.60 on Dec. 6. 89bio is developing a fibroblast growth factor (FGF) 21 analog, BIO89-100, in...


Sign up to our weekly BioTuesdays newsletter.